Home         Forums  

Go Back   Marrowforums > Treatments > Drugs and Drug Treatments
Register FAQ Search Today's Posts Mark Forums Read

Drugs and Drug Treatments ATG, Cyclosporine, Revlimid, Vidaza, Dacogen, ...

Reply
 
Thread Tools Search this Thread
  #1  
Old Sat Nov 3, 2007, 03:19 PM
Birgitta-A Birgitta-A is offline
Member
 
Join Date: Oct 2007
Location: Stockholm, Sweden
Posts: 1,918
Low SerumEPO associated with good Aranesp/Procrit/Epogen response

Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis.
Oncologist. 2007 Oct;12(10):1264-73
Ross SD et al
F.R.C.P.C., United BioSource Corporation, 101 Station Landing, Medford,
Massachusetts 02155, USA. Susan.ross@unitedbiosource.com.

Objective
The objective was to assess the efficacy and safety of erythropoiesis-stimulating proteins (ESPs) in anemia of myelodysplastic syndrome (MDS).

Method
A systematic review and meta-analysis was conducted covering English-language studies published from 1980 to December 2005.

Results
Fifty-nine studies qualified: five controlled trials (n = 354), all epoetin versus control (EvC); 51 epoetin (Procrit/Epogen) single-arm studies (n = 1,650); and three darbepoetin (Aranesp) single-arm studies (n = 102).

In the EvC studies, epoetin patients demonstrated a significant advantage over controls in terms of hemoglobin (Hb) response (odds ratio, 5.2; 95% confidence interval, 2.5-10.8). Hb response was 48.1% in single-arm darbepoetin studies, 32.1% in epoetin single-arm studies, and 27.3% in EvC studies.

Major Hb response averaged 38.8% in darbepoetin studies, 24.5% in epoetin single-arm studies, and 11.4% in EvC studies. Stratified analyses suggest that lower baseline erythropoietin levels, longer treatment durations, and concurrent iron may be associated with greater Hb response to ESPs.

None of the analyzable predictors of Hb response (gender, baseline Hb, ESP type, and ESP duration) were significant in meta-regression analyses.

In the few studies with quality-of-life measures, ESP groups attained a pre-post change (Functional Assessment of Cancer Therapy - Fatigue) that exceeded minimum clinically important differences. Selected adverse event rates did not differ between the epoetin and darbepoetin groups.

Conclusion
Published studies suggest that ESPs are efficacious in anemia of MDS. Hb response appears higher in darbepoetin patients than in epoetin patients, and safety appears comparable, but darbepoetin data are sparse, and there are as yet no direct comparison studies.
Kind regards
Birgitta
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Low Reticulocyte Count without Anemia alevoy18 Bone Marrow Failure 12 Sun May 29, 2016 10:40 PM
Treatment for Low WBC in Aplastic Anemia KMac AA 9 Mon May 6, 2013 12:12 PM
Low Lymphocytes, low retic & lymph nodes swollen alevoy18 Tell Your Story 3 Thu Aug 26, 2010 07:50 AM
Revlimid response, low platelets and transfusion independence Birgitta-A Drugs and Drug Treatments 1 Wed Jan 14, 2009 12:27 PM


All times are GMT -4. The time now is 07:47 AM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2021, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright 2006-2020 Marrowforums.org